High dose cytosine arabinoside (HDARAC) in refractory acute leukemia

Seth A. Rudnick, Edwin C. Cadman, Robert L. Capizzi, Roland T. Skeel, Joseph Bertino, Sue McIntosh

Research output: Contribution to journalArticlepeer-review

245 Scopus citations


Thirteen leukemic patients with disease refractory to conventional chemotherapy were treated with 1.0 to 7.5 g/m2 of Cytosine Arabinoside (Ara‐C) over 29 drug cycles. Drug infusions were spaced at 12‐hour intervals; a maximum of four doses was administered over 36 hours. After single dose tolerance had been established, three or four dose cycles were given at 2‐ to 30‐day intervals. There were three partial remissions (PR) and one complete remission (CR) in a treatment group of four patients with AML, five with ALL, two with lymphoma converted to leukemic phase, one CML in blast crisis, and one promyelocytic leukemia. Five of the patients were septic and considered terminally ill at the time of treatment. All other patients had evidence of drug responsiveness. The nadir of the white count occurred from 3 to 12 days after treatment, with subsequent recovery of the peripheral granulocyte count between days 12 and 28. Toxicity included nausea and vomiting (GI symptoms) in twelve patients, central nervous system (CNS) disturbances in eight patients, one episode of inappropriate antidiuretic hormone syndromes (SIADH), one of hyperuricemia, and fever in eleven patients. There was no evidence of hepatic or renal dysfunction. These high doses of Ara‐C appear useful for treatment of patients with refractory leukemia. Hospitalization is brief and toxicity acceptable.

Original languageEnglish (US)
Pages (from-to)1189-1193
Number of pages5
Issue number4
StatePublished - Oct 1979

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'High dose cytosine arabinoside (HDARAC) in refractory acute leukemia'. Together they form a unique fingerprint.

Cite this